Clinical Trials Directory

Trials / Completed

CompletedNCT01890213

Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer

A Pilot Study of Active Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
12 (estimated)
Sponsor
Duke University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a pilot study to evaluate the safety of a vaccine that consists of an alphavirus replicon (VRP) encoding the protein (CEA) that has been found to be associated with cancers such as colon cancer in patients that have stage III colon cancer. We will also evaluate the patient immune response to the vaccine.

Conditions

Interventions

TypeNameDescription
BIOLOGICALAVX701

Timeline

Start date
2013-11-01
Primary completion
2017-06-01
Completion
2019-07-01
First posted
2013-07-01
Last updated
2019-07-18

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01890213. Inclusion in this directory is not an endorsement.